TABLE 2.
Summary of 5-HVLX-Gluc Plasma Pharmacokinetic Parameters
| Parameter | Viloxazine Extended-Release Alone (n = 34) | Combination (n = 34) |
|---|---|---|
| Cmax, μg/mL | 3.44 ± 0.73 (21.22) | 3.24 ± 0.63 (19.50) |
| AUC0-t, h*μg/mL | 70.30 ± 12.27 (17.46) | 66.60 ± 10.56 (15.86) |
| AUCinf, h*μg/mL | 70.44 ± 12.28 (17.43) | 66.72 ± 10.56 (15.82) |
| Tmax, h [median (range)] | 6.00 (5.00–12.00) | 5.50 (4.00–12.00) |
| t1/2, h | 6.86 ± 2.81 (40.97) | 6.62 ± 2.11 (31.84) |
| Metabolite-to-Parent (5-HVLX-gluc to Viloxazine) Ratios | ||
| Cmax | 0.395 ± 0.101 (25.52) | 0.384 ± 0.082 (21.29) |
| AUC0-t | 0.396 ± 0.111 (27.94) | 0.372 ± 0.089 (23.78) |
| AUCinf | 0.393 ± 0.109 (27.81) | 0.365 ± 0.084 (23.12) |
All data reported as mean ± SD (CV%) unless otherwise specified.
Metabolite-to-parent ratios are adjusted based on the molecular weights of viloxazine (237) and 5-HVLX-gluc (429).